This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Galectin Therapeutics Presents New Data On The Treatment Of Fatty Liver Disease And Fibrosis At AASLD 2012

Stocks in this article: GALT

Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today presented new preclinical data on the mechanism of action of GR-MD-02 at the American Association for the Study of Liver Disease (AASLD) Annual Meeting in Boston, MA. GR-MD-02 is the Company’s lead galectin inhibitor in development for the treatment of non-alcoholic steatohepatitis (NASH), or fatty liver disease. These new data help to further explain the mechanism of action of GR-MD-02, showing that this galectin inhibitor affects multiple pathways involved with both the prevention and reversal of fibrosis in NASH pathology.

“The data presented at AASLD further elucidate the mechanism of how galectin inhibition affects liver fibrosis in preclinical models of disease, resulting in the prevention and reversal of fibrosis,” said Peter G. Traber, MD, President, Chief Executive Officer and Chief Medical Officer, Galectin Therapeutics. “As we continue to advance GR-MD-02 for the treatment of NASH with advanced fibrosis, we are hopeful that galectin inhibition could provide patients with a novel treatment option, where liver transplantation is currently the only therapy available. GR-MD-02 is expected to enter the clinic in the first quarter of 2013.”

The presentation, entitled “Galectin-3 targeting drugs inhibit multiple pathological pathways leading to improvement of non-alcoholic steatohepatitis (NASH)”, was authored by Peter G. Traber and Eliezer Zomer. As previously demonstrated, GR-MD-02 treatment in a mouse model of NASH resulted in marked improvement in liver histology with significant reduction in steatosis, ballooning and inflammation, as well as fibrosis, determined by Sirius red staining. This disease improvement upon treatment with GR-MD-02 was seen when animals were treated early in disease (disease prevention) or after fibrosis had been established (disease reversal).

The new data show that Galectin-3 protein expression was markedly increased in animals with NASH, and those levels were dramatically reduced to barely detectable levels following treatment with GR-MD-02. Elevated expression of iNOS, an important inflammatory mediator, and CD36, a scavenger receptor involved in the pathogenesis of NASH, were markedly reduced following treatment with GR-MD-02. Alpha-smooth muscle actin, a marker used to identify activated cells that cause liver fibrosis, showed increased numbers of cells in control livers, which was markedly reduced in livers treated with GR-MD-02. Together, these data suggest that GR-MD-02 works to prevent or reverse fibrosis in NASH by reducing galectin-3, which is associated with multiple pathogenic effects.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,273.76 -106.65 -0.65%
S&P 500 1,886.76 +24.00 1.29%
NASDAQ 4,258.4380 +41.0480 0.97%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs